Printer Friendly


Swedish Orphan Biovitrum AB has received orphan drug designation in Switzerland for its extended half-life haemophilia drug candidate Alprolix (rFIXFc) developed for the treatment of haemophilia B. An orphan drug designation is to encourage the development of medicines for rare diseases and provides orphan status to drugs and biologic sunder development.

Haemophilia B is caused by having substantially reduced or no factor IX activity, which is needed for normal blood clotting. People with haemophilia B may experience bleeding episodes in joints and muscles that cause pain, decreased mobility, and irreversible joint damage, and in worst cases organ bleeds and life-threatening haemorrhages. Infusions of factor IX temporarily replace clotting factors necessary to resolve bleeding and when used prophylactically to prevent new bleeding episodes. Alprolix, a recombinant factor IX concentrate candidate with prolonged circulation in the body, is believed to offer improved and prolonged protection in the control and prevention against such bleeding episodes.

The World Federation of Hemophilia global survey conducted in 2013 estimates that approximately 28,430 people are currently diagnosed with haemophilia B worldwide.

About Alprolix

Alprolix (rFIXFc) is an extended half-life recombinant factor IX Fc fusion protein product candidate for people with haemophilia B. Alprolix was submitted to the European Medicines Agency (EMA) for regulatory approval in Europe in June 2015. Alprolix was developed by fusing factor IX to the Fc portion of immunoglobulin G subclass 1, or IgG1 (a protein commonly found in the body). This enables Alprolix to use a naturally occurring pathway to prolong the time the therapy remains in the body.

Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein], is the first recombinant, clotting factor therapy with prolonged circulation in the body for adults and children with haemophilia B, approved in the United States, Canada, Australia and Japan.

About the Sobi and Biogen collaboration

Sobi and Biogen are collaboration partners in the development and commercialization of Alprolix/rFIXFc for haemophilia B. Sobi has final development and commercialization rights for rFIXFc in the Sobi territory (essentially Europe, North Africa, Russia and most Middle Eastern markets). Biogen leads development for Alprolix/rFIXFc, has manufacturing rights, and has commercialisation rights in North America and all other regions in the world excluding the Sobi territory.

About Sobi

Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi develops and delivers therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion (USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm.

For more information, visit or call 347/224-0819.

COPYRIGHT 2016 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Worldwide Biotech
Date:Feb 1, 2016

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters